Does chemotherapy increase survival in patients with metastatic prostate cancer?
Best insight from top research papers
Chemotherapy has been shown to increase overall survival in patients with metastatic prostate cancer. Several studies have demonstrated the survival benefit of chemotherapy in this patient population. In a multicenter randomized phase III trial, the administration of docetaxel and prednisone every 3 weeks, as well as weekly administration of docetaxel and prednisone, resulted in improved postprogression survival . Additionally, real-world data from the Surveillance, Epidemiology, and End Results (SEER) database showed that chemotherapy-exposed patients had better overall survival compared to chemotherapy-naive patients . These findings highlight the importance of chemotherapy in improving survival outcomes for patients with metastatic prostate cancer.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
4 Citations | Yes, chemotherapy was associated with better overall survival in patients with metastatic prostate cancer. |
3 Citations | Chemotherapy increases survival in patients with metastatic castration-resistant prostate cancer (mCRPC), but the survival benefit varies depending on the volume of disease and the treatment received in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. |
| The paper does not directly answer the question about whether chemotherapy increases survival in patients with metastatic prostate cancer. The paper focuses on predicting postprogression survival following chemotherapy in men with castration-resistant metastatic prostate cancer. | |
| The paper does not directly answer the question about whether chemotherapy increases survival in patients with metastatic prostate cancer. The paper focuses on predicting postprogression survival following chemotherapy in men with castration-resistant metastatic prostate cancer. | |
3 Citations | Chemotherapy can increase survival in patients with metastatic prostate cancer, particularly in those with de novo and metachronous high-volume disease. |
Related Questions
How metastatic cancer kills?5 answersMetastatic cancer kills through a complex process involving various biological events. The tumor-stromal interface plays a crucial role in the initiation of metastasis, where tumor cells interact with stromal cells and undergo epithelial-mesenchymal transition (EMT). Circulating tumor cells (CTCs) are formed when tumor cells intravasate into the bloodstream, aided by stromal cross-talk and abnormal vasculature. CTCs can then adhere to secondary organs and form disseminative tumor cells (DTCs), which can either remain dormant or proliferate. The process of metastatic outgrowth is influenced by factors such as macrophage activity, impaired autophagy, and secondary site inflammation. Targeting metastasis can be achieved by repressing pre-metastatic niche formation, suppressing environmental stressors, and targeting signaling pathways and cell types involved in the metastatic process. These strategies can be used in combination with other therapies, such as immunotherapy, to limit the aggressive spread of metastatic cancer.
What is the percentage of patients with metastatic castration resistant prostate cancer who are in third line therapy?5 answersThe percentage of patients with metastatic castration-resistant prostate cancer (mCRPC) who are in third-line therapy varies across the studies. One study found that 81 out of 166 patients (49%) received third-line treatment. Another study identified a high-risk subgroup in which no meaningful benefit from third-line life-prolonging drugs (LPDs) was derived, suggesting that not all mCRPC patients receive third-line therapy. Additionally, a study evaluating first-line treatment in mCRPC patients mentioned the use of third-line agents, but did not provide specific percentages. Another study compared the efficacy of 177Lu prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment, but did not report the percentage of patients in third-line therapy. Lastly, a study comparing treatment outcomes with cabazitaxel reported that 66 out of 94 patients (70%) received cabazitaxel as third-line therapy. Therefore, the percentage of patients in third-line therapy for mCRPC varies across the studies, ranging from 49% to 70%.
What are the latest advances in the treatment of metastatic castration-resistant prostate cancer?5 answersRecent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) include the approval of Pluvicto, a targeted radioligand therapeutic agent that selectively attacks PSMA-positive cells. Other targeted agents, such as poly ADP ribose polymerase (PARP) inhibitors, have shown efficacy in patients with homologous recombination repair-deficient tumors. Additionally, radiopharmaceuticals like radium-223 and lutetium-177 have demonstrated promising activity in metastatic pretreated prostate cancer patients. Combining androgen deprivation, docetaxel, and additional androgen-receptor-targeted therapies in treatment-naïve metastatic prostate cancer has also shown potential to improve outcomes. These advancements in treatment options for mCRPC are based on a better understanding of the biology of prostate cancer and the identification of potential treatment targets and predictive biomarkers. The goal is to improve overall efficacy and provide more personalized and biomarker-driven treatment selection for patients with advanced prostate cancer.
Can Stage 2 cancer metastasize?10 answers
Can chemo reverse metastatic cancer?10 answers
What is the best treatment for metastatic squamous cell carcinoma?9 answers